Category Archives: Global News Feed

Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board

Read more:
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Ariadne Jerue, who joined Oncternal as Associate Director, Clinical Operations.

Go here to read the rest:
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Following the successful experience of customers in the US and APAC, the adoption of the HD kit is expanding across multiple geographic regions Following the successful experience of customers in the US and APAC, the adoption of the HD kit is expanding across multiple geographic regions

More here:
Biolog-id Launches an Innovative High-Density (HD) RFID Kit Targeting the High-Volume Needs of Blood Centers and Large Hospital Blood Banks

PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today announced changes to its board composition and management team.

Read more here:
AnPac Bio Announces Board and Management Changes

Basel, 4 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

See more here:
Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU

Building upon Infant Bacterial Therapeutics AB’s (IBT) unique expertise in developing treatment solutions for preterm infants, IBT is at an early stage of investigating the possibilities of developing a drug to prevent retinopathy of prematurity, a growing and serious condition that often leads to blindness among prematurely born babies. The FDA granted orphan drug designation for IBT’s product on Sep 20th .

Go here to read the rest:
FDA approves Infant Bacterial Therapeutics' request for a new orphan drug designation

VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has submitted a notice of work with the BC Ministry of Mines, for the removal of 2,000 tonnes of barium sulfate from its Frances Creek Project. The Frances Creek project is one of the company’s three 100% owned projects in British Columbia with grade suitable for the pharmaceutical barite marketplace.

Follow this link:
InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals’ Notice of Work with the BC Ministry of Mines, for the Removal of 2,000 Tonnes of...

Significant Milestone in Commercialization Plan Expected to Drive Sales Momentum Significant Milestone in Commercialization Plan Expected to Drive Sales Momentum

See the article here:
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m. ET on Thursday, September 29, 2022, in New York, NY.

Continue reading here:
ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit

– Phase 2 trial met primary and secondary endpoints with statistical significance in reducing signs and symptoms associated with cervical dystonia (CD) in adults –

Read more here:
AEON Biopharma Reports Positive Topline Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia